Eli Casdin - Jul 19, 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role: Director, 10%+ Owner
Signature: /s/ Eli Casdin by Agnieszka Gallagher, Attorney-in-Fact
Stock symbol: LAB
Transactions as of: Jul 19, 2024
Transactions value $: $0
Form type: 4
Date filed: 7/23/2024, 06:05 PM
Previous filing: Jul 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LAB	Common Stock	Award	$0	+1.59K	+0.06%	$0.00	2.75M	Jul 19, 2024	Direct	F1, F2
holding	LAB	Common Stock						13.9M	Jul 19, 2024	Casdin Private Growth Equity Fund II, L.P.	F3
holding	LAB	Common Stock						2.74M	Jul 19, 2024	By Casdin Private Growth Equity Fund, L.P.	F4
holding	LAB	Common Stock						18.9K	Jul 19, 2024	See footnote	F5
holding	LAB	Common Stock						46.7M	Jul 19, 2024	Casdin Partners Master Fund, L.P	F6
holding	LAB	Common Stock						545K	Jul 19, 2024	Casdin Amplify Fund, LP	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Restricted Stock Units ("RSUs") that vest as to 25% on July 23, 2024 and thereafter in two equal installments on the 15th day of the last month of each remaining fiscal quarter of 2024, subject to the Reporting Person's continued service through the applicable vesting date.
F2	The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $3,750 in cash compensation for services as a board member.
F3	The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F4	The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
F5	The securities are indirectly owned by Eli Casdin who has voting and investment discretion with respect to the securities.
F6	The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
F7	The securities are owned directly by Casdin Amplify Fund, LP ("Amplify") and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin and the GP.

Remarks:

The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.